Fecal DNA Testing for Colorectal Cancer Screening

Annual Review of Medicine

Volumn 71, Issue , 2020, Pages 59-69

  Carethers, John M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

colorectal cancer screening; fecal DNA tests; multitarget stool DNA test; stool DNA tests

Indexed keywords

BIOLOGICAL MARKER; DNA;

CANCER SCREENING; COLON ADENOMA; COLON POLYP; COLONOSCOPY; COLORECTAL CANCER; COMPARATIVE EFFECTIVENESS; COST BENEFIT ANALYSIS; DNA DETERMINATION; EPIGENETICS; FECES ANALYSIS; HUMAN; IMMUNOCHEMISTRY; PRIORITY JOURNAL; REVIEW; VALIDATION STUDY; AGED; COLORECTAL TUMOR; CROSS-SECTIONAL STUDY; EARLY CANCER DIAGNOSIS; ECONOMICS; FECES; FEMALE; GENETICS; MALE; MIDDLE AGED; PATHOLOGY; PRECANCER; PROCEDURES; SENSITIVITY AND SPECIFICITY;

AGED; COLONIC POLYPS; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; CROSS-SECTIONAL STUDIES; DNA, NEOPLASM; EARLY DETECTION OF CANCER; FECES; FEMALE; HUMANS; MALE; MIDDLE AGED; PRECANCEROUS CONDITIONS; SENSITIVITY AND SPECIFICITY;

EID: 85077663743     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-103018-123125     Document Type: Review

References (46)

1. Siegel RL, Miller KD, Jemal A. 2019. Cancer statistics, 2019. CA Cancer J. Clin. 69:7-34
2. Nishihara R, Wu K, Lochhead P, et al. 2013. Long-Term colorectal-cancer incidence and mortality after lower endoscopy.N. Engl. J. Med. 369:1095-105
3. Zauber A, Winawer SJ, OBrien MJ, et al. 2012. Colonoscopic polypectomy and long-Term prevention of colorectal-cancer deaths.N. Engl. J. Med. 366:687-96
4. Shaukat A, Mongin SJ, GeisserMS, et al. 2013. Long-Termmortality after screening for colorectal cancer. N. Engl. J. Med. 369:1106-14
5. Rex DK, Boland CR, Dominitz JA, et al. 2017. Colorectal cancer screening: recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Gastroenterology 153:307-23
6. Carethers JM. 2015. Screening for colorectal cancer in African Americans: determinants and rationale for an earlier age to commence screening. Digest. Dis. Sci. 60:711-21
7. Ahlquist DA. 2015. Multi-Target stool DNA test: A new high bar for noninvasive screening. Digest. Dis. Sci. 60:623-33
8. Lin JS, Webber EM, Beil TL, et al. 2012. Fecal DNA testing in screening for colorectal cancer in averagerisk adults: comparative effectiveness review. Executive summary no. 52. AHRQ Pub. No. 12-EHC022-1. Rockville, MD: Agency for Healthcare Research and Quality. https://effectivehealthcare.ahrq.gov/sites/default/files/related-files/colorectal-cancer-screening-executive.pdf. Accessed June 1, 2019
9. Carethers JM. 2014. DNA testing and molecular screening for colon cancer. Clin. Gastroenterol. Hepatol. 12:377-81
10. Grady WM, Carethers JM. 2008. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 135:1079-99
11. Carethers JM, Jung BH. 2015. Genetics and genetic biomarkers in sporadic colorectal cancer. Gastroenterology 149:1177-90
12. Cancer Genome Atlas Network. 2012. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330-37
13. Carethers JM. 2016. Hereditary, sporadic and metastatic colorectal cancers are commonly driven by specific spectrums of defective DNA mismatch repair components. Trans. Am. Clin. Climatol. Assoc. 127:81-97
14. Carethers JM. 2017. Microsatellite instability pathway and EMAST in colorectal cancer. Curr. Colorectal Cancer Rep. 13:73-80
15. Carethers JM, Fearon ER. 2015. Molecular subtyping of colorectal cancer: Time to explore both intertumoral and intratumoral heterogeneity to evaluate patient outcome. Gastroenterology 148:10-13
16. Koi M, Garcia M, Choi C, et al. 2016. Microsatellite alterations with allelic loss on 9p24.2 signify less aggressive colorectal cancer metastasis. Gastroenterology 150:944-55
17. Coppede F, Lopomo A, Spisni R, Migliore L. 2014. Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer.World J. Gastroenterol. 20:943-56
18. Carethers JM. 2015. Biomarker-directed targeted therapy in colorectal cancer. J. Digest. Cancer Rep. 3:5-10
19. Klaassen CH, JeuninkMA, Prinsen CR, et al. 2003. Quantification of human DNA in feces as a diagnostic test for the presence of colorectal cancer. Clin. Chem. 49:1185-87
20. Anderson BW, Ahlquist DA. 2016. Molecular detection of gastrointestinal neoplasia. Gastroenterol. Clin. N. Am. 45:529-42
21. Sidransky D, Tokino T, Hamilton SR, et al. 1992. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 256:102-5
22. Zou H, Taylor WR, Harrington JJ, et al. 2009. High detection rates of colorectal neoplasia by stool DNA testing with a novel digital melt curve assay. Gastroenterology 136:459-70
23. Ahlquist DA, Sargent DJ, Loprinzi CL, et al. 2008. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann. Intern.Med. 149:441-50
24. Shen L, Toyota M, Kondo Y, et al. 2007. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc. Natl. Acad. Sci. USA 104:18654-59
25. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. 2004. FecalDNAversus fecal occult blood for colorectal cancer screening in an average-risk population.N. Engl. J. Med. 35:2704-14
26. Bailey JR, Aggarwal A, Imperiale TF. 2016. Colorectal cancer screening: stool DNA and other noninvasive modalities. Gut Liver 10:204-11
27. Exact Sciences Corp.Cologuard® physician brochure.Madison, WI: Exact Sciences Corp. https://cdn2.hubspot.net/hub/377740/file-1412311339-pdf/Document-LBL-0260[1].pdf?t=1534449532931. Accessed June 1, 2019
28. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. 2014. Multitarget stool DNA testing for colorectalcancer screening.N. Engl. J. Med. 370:1287-97
29. Ahlquist DA, Zou H, Domanico M, et al. 2012. Next generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology 142:248-56
30. Redwood DG, Asay ED, Blake ID, et al. 2016. Stool DNA testing for screening detection of colorectal neoplasia in Alaska native people. Mayo Clin. Proc. 91:61-70
31. Yang D, Hillman SL, Harris AM, et al. 2014. Patient perceptions of a stool DNA testing for pan-digestive cancer screening: A survey questionnaire.World J. Gastroenterol. 20:4972-79
32. Cooper GS, Markowitz SD, Chen Z, et al. 2018. Evaluation of patients with an apparent false positive stool DNA test: The role of repeat stool testing. Digest. Dis. Sci. 63:1449-53
33. Johnson DH, Kisiel JB, Burger KN, et al. 2017. Multitarget stool DNA test: clinical performance and impact on yield and quality of colonoscopy for colorectal cancer screening. Gastrointest. Endosc. 85:657-65
34. Brenner H, Chen H. 2017. Fecal occult blood versus DNA testing: indirect comparison in a colorectal cancer screening population. Clin. Epidemiol. 9:377-84
35. Zhai R-L, Xu F, Zhang P, et al. 2016. The diagnostic performance of stool DNA testing for colorectal cancer. Medicine 95:e2129
36. Levin TR, Corley DA, Jensen CD, et al. 2017. Genetic biomarker prevalence is similar in fecal immunochemical test positive and negative colorectal cancer tissue.Digest. Dis. Sci. 62:678-88
37. Heigh RI, Yab TC, Taylor WR, et al. 2014. Detection of colorectal serrated polyps by stool DNA testing: comparison with fecal immunochemical testing for occult blood (FIT). PLOS ONE 9:e85659
38. CooperGS, Markowitz SD, Chen Z, et al. 2018. Performance ofmultitarget stool DNA testing in African American patients. Cancer 124:3876-80
39. Berger BM, Schroy PC III, DinhTA. 2016. Screening for colorectal cancer using amultitarget stoolDNA test: modeling the effect of the interest interval on clinical effectiveness. Clin. Colorectal Cancer 15:e65-74
40. Zauber AG, Lansdorp-Vogelaar I, Wilschut J, et al. 2007. Cost-effectiveness of DNA stool testing to screen for colorectal cancer. Technology Assessment Report. Rockville, MD: Agency for Healthcare Research and Quality. https://www.ncbi.nlm.nih.gov/books/NBK285164/. Accessed June 1, 2019
41. Landsdorp-Vogelaar I, Kuntz KM, Knudsen AB, et al. 2010. Stool DNA testing to screen for colorectal cancer in the Medicare population: A cost-effectiveness analysis. Ann. Intern.Med. 153:368-77
42. Ladabaum U, Mannalithana A. 2016. Comparative effectiveness and cost effectiveness of a multitarget stool DNA test to screen for colorectal neoplasia. Gastroenterology 151:427-39
43. Barzi A, Lenz HJ, Quinn DI, Sadeghi S. 2017. Comparative effectiveness of screening strategies for colorectal cancer. Cancer 123:1516-27
44. Bibbins-Domingo K, GrossmanDC, Curry SJ, et al. 2016. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA 315:2564-75
45. Knudsen AB, Zauber AG, Rutter CM, et al. 2016. Estimation of benefits, burden, and harms of colorectal cancer screening strategies: modeling study for theU.S. Preventive ServicesTask Force. JAMA 315:2595-609
46. Suehiro Y, Zhang Y, Hashimoto S, et al. 2018. Highly sensitive faecal DNA testing of TWIST1 methylation in combination with faecal immunochemical test for haemoglobin is a promisingmarker for detection of colorectal neoplasia. Ann. Clin. Biochem. 55:59-68